Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...
Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease ...
A study conducted at the lab of Beth Stevens, Ph.D., at Boston Children's Hospital, has revealed that an immune protein impacts neuronal protein synthesis in the aging brain. Previous work from the ...
Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results